IL23R and inflammatory bowel disease: However, homozygous carriers of IBD risk‐increasing IL23R variants were more likely to respond to IFX than homozygous carriers of IBD risk‐decreasing IL23R variants (74.1 vs. 34.6%; p = 0.001) [35].